MedTrace Logo

A Study of Brain Receptor Occupancy in Healthy Subjects

NCT01232439 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2011-05-09

No results posted yet for this study

Summary

To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.

Conditions

  • Alcohol Dependence

Interventions

DRUG

opioid receptor kappa antagonist

Starting dose of 2 mg, administered orally, once. The potential dose range for this study is 0.2 mg to 30 mg

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01232439 on ClinicalTrials.gov